Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 2 completed trials

    Completion Rate
    100%(2/2)
    Active Trials
    0(0%)
    Results Posted
    0%(0 trials)

    Phase Distribution

    Not Applicable
    2
    100%

    Phase Distribution

    0

    Early Stage

    0

    Mid Stage

    0

    Late Stage

    Phase Distribution2 total trials
    N/ANon-phased studies
    2(100.0%)

    Highest Phase Reached

    Unknown

    Trial Status & Enrollment

    Completion Rate

    100.0%

    2 of 2 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    2

    all time

    Status Distribution
    Completed(2)

    Detailed Status

    Completed2

    Development Timeline

    Analytics

    Development Status

    Total Trials
    2
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    N/A

    Trials by Phase

    N/A2 (100.0%)

    Trials by Status

    completed2100%

    Recent Activity

    0 active trials
    Showing 2 of 2
    completednot_applicable

    Phase II Trial of Neo-adjuvant Temozolomide Prior to Combined Temozolomide and Concurrent Accelerated Hypofractionated External Beam Radiotherapy Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

    NCT01702610
    completednot_applicable

    Hypofractionated Intensity Modulated Radiation Therapy Plus Hormonal Therapy in Patients With High Risk Prostate Cancer

    NCT02107287

    Clinical Trials (2)

    Showing 2 of 2 trials
    NCT01702610Not Applicable

    Phase II Trial of Neo-adjuvant Temozolomide Prior to Combined Temozolomide and Concurrent Accelerated Hypofractionated External Beam Radiotherapy Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

    Completed
    NCT02107287Not Applicable

    Hypofractionated Intensity Modulated Radiation Therapy Plus Hormonal Therapy in Patients With High Risk Prostate Cancer

    Completed

    All 2 trials loaded

    Drug Details

    Intervention Type
    Radiation
    Total Trials
    2